Holen Sie sich die Stockscreener-App
6.33
8.95%
0.52
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Real time alert setup for Replimune Group Inc. performanceJuly 2025 Pullbacks & Low Volatility Stock Suggestions - Newser
Securities Fraud Class Action Filed Against Replimune Group, Inc. (REPL)Levi & Korsinsky Reminds Investors of September 22, 2025 - ACCESS Newswire
Assessing Legal and Market Risks in Replimune Group, Inc. (REPL) Amid Ongoing Class Action Lawsuits - AInvest
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - The Malaysian Reserve
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL - FinancialContent
מועד אחרון לתביעה נגד REPL: רוזן, יועץ למשקיעים גלובלי, מעודד את משקיעי Replimune Group, Inc. שצברו הפסדים של יותר מ- 100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב בתביעה ייצוגית בניירות ערך שהוגשה ראשונה על ידי המשרד – REPL - GlobeNewswire Inc.
Replimune Group, Inc. (REPL) Investors: September 22, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - NewMediaWire
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - PR Newswire
Replimune Group, Inc. Investors: Please contact the Portnoy - GlobeNewswire
Shareholders SueWallSt in New Class Action Against Replimune Group, Inc.Act Now - Nasdaq
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - Morningstar
Will Replimune Group Inc. continue its uptrend2025 Technical Patterns & Stepwise Entry/Exit Trade Alerts - Newser
Securities Fraud and Shareholder Risk at Replimune Group (REPL): Assessing the Financial and Reputational Impact of Securities Litigation on Biotech Valuations - AInvest
Full technical analysis of Replimune Group Inc. stockJuly 2025 Review & Low Risk High Win Rate Stock Picks - Newser
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class Action – Contact Levi & Korsinsky - ACCESS Newswire
Replimune Group Schedules Crucial FDA Meeting for RP1 - TipRanks
The Gross Law Firm Announces the Filing of a Securities - GlobeNewswire
Replimune Group, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsREPL - Business Wire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial InadequateHagens Berman - PR Newswire
September 22, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against REPL - PR Newswire
Replimune's Regulatory Setback and Legal Exposure: A Cautionary Tale for Biotech Investors - AInvest
Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug ApprovalHagens Berman - PR Newswire
Replimune Group Inc. stock trend outlook and recovery pathLong Setup & Expert Approved Momentum Trade Ideas - Newser
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Levi & Korsinsky Urges Replimune Group, Inc. (REPL) Shareholders to Act Before Lead Plaintiff Deadline September 22, 2025 - ACCESS Newswire
Ranking Replimune Group Inc. among high performing stocks via toolsGap Up & Growth Focused Stock Reports - Newser
American Century Companies Inc. Grows Stake in Replimune Group, Inc. $REPL - Defense World
Developing predictive dashboards with Replimune Group Inc. dataJuly 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - WV News
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire
Replimune’s Regulatory Crossroads: Can RP1 Navigate FDA Hurdles in Advanced Melanoma? - AInvest
Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL)Recover LossesContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Can you recover from losses in Replimune Group Inc.July 2025 Breakouts & Free Community Consensus Stock Picks - Newser
Risk vs reward if holding onto Replimune Group Inc.2025 Retail Activity & Precise Swing Trade Entry Alerts - Newser
Replimune stock gains on FDA Type A meeting (REPL:NASDAQ) - Seeking Alpha
What Fibonacci levels say about Replimune Group Inc. reboundMarket Risk Report & Real-Time Buy Signal Alerts - Newser
What’s the recovery path for long term holders of Replimune Group Inc.Trade Ideas & Daily Profit Maximizing Tips - Newser
What MACD signals say about Replimune Group Inc.Index Update & Consistent Growth Equity Picks - Newser
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Class Action Reminder for REPL Investors: Kessler Topaz Meltzer & Check, LLP Reminds Replimune Group, Inc. (REPL) Investors of Securities Fraud Class Action Lawsuit - WV News
Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key DrugHagens Berman - GlobeNewswire
Levi & Korsinsky Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineREPL - WV News
Replimune Announces Type A Meeting Scheduled with FDA - The Manila Times
Critical FDA Meeting Scheduled: Replimune's Advanced Melanoma Treatment Faces Decisive Moment - Stock Titan
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Shareholders of Class Action Lawsuit and September 22, 2025 Deadline - ACCESS Newswire
Detecting support and resistance levels for Replimune Group Inc.Market Activity Summary & AI Driven Stock Price Forecasts - Newser
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
Class Action Lawsuit Filed: Replimune Group, Inc. (REPL)Join by September 22, 2025 – Contact Levi & Korsinsky - ACCESS Newswire
Can Replimune Group Inc. continue delivering strong returnsQuarterly Market Summary & Proven Capital Preservation Tips - خودرو بانک
Lost Money on Replimune Group, Inc. (REPL)? Join Class Action Before September 22, 2025Contact Levi & Korsinsky - ACCESS Newswire
Replimune Faces Big Swings After FDA Setback And Cash Concerns - Finimize
News impact scoring models applied to Replimune Group Inc.Portfolio Update Report & Weekly Setup with High ROI Potential - Newser
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):